Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-CD28 family: significant co-stimulatory pathway in immune regulation

B7-CD28 family: significant co-stimulatory pathway in immune regulation

Background

Based on the recognition of antigens in the adaptive immune response, T cell activity is largely achieved during activation, where two signals are required. First, T cell receptors must specifically engage peptides presented by major histocompatibility complexes (MHCs) on antigen presenting cells (APCs); secondly, co-stimulatory/ co-inhibitory receptors on T cells must bind B7 ligand family expressed on APCs to regulate situation of T cell.

This provides a key checkpoint in the regulation of T cell immunity. T cell activation is regulated by the innate immune system through positive and negative costimulatory molecules. Members of the B7 family have been shown to be important for regulating T cell responses. So B7 ligand family plays a significance role in human cancers and autoimmune diseases. The B7 ligand family comprises 11 members, which are B7-1, B7-2, B7-H1, B7-DC, B7-H2, B7-H3, B7-H4, B7-H5, BTNL2, B7-H6 and B7-H7.

ACROBiosystems has developed exclusive B7 family proteins with high purity and high bioactivity, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments, and can accelerate the development of antibody drugs.

B7-H3
B7-DC
B7-H1
B7-1
B7-2
MHC-11
B7-H2
B7-H4
B7-H5
B7-H7
BTNK-2
B7-H6
TLT-2
PD-1
B7-H1
CD28
CTLA-4
CD3
CD3
ICOS
VISTA
TMIGD2
NKp30
APC
T Cell
ITAM
Actived T Cell
NKC
Second Signal
Second Signal
TCR
First Signal

Stimulatory signal Inhibitory signal

Arrows indicate interaction between receptor and ligand of B7 family members

Click the molecule name to view product details

Sketch of B7 family molecules
B7 family ligand Ligand alias Expression Putative receptors Role in T/NK cell responses
Immune cells Tumor
B7-H1 PD-L1,CD274,PDCD1LG1 + + PD-1,CD80 Inhibition
B7-DC PD-L2,CD273,PDCD1LG2 + + PD-1,RGMB Inhibition
B7-1 CD80,BB1,LAB-7,CD28LG1 + CD28,CTLA-4, PD-L1 Activation/Inhibition
B7-2 CD86,B70,LAB72,CD28LG2 + CD28,CTLA-4 Activation/Inhibition
B7-H3 CD276,B7RP-2 + + Unidentified Activation/Inhibition
B7-H5 VISTA,GI24,VSIR,SISP1,PD1H,DD1α + - VSIG3 Inhibition
B7-H2 ICOS-L,ICOSLG,GL50,B7RP1,LICOS + ICOS,CD28,CTLA-4 Activation
B7-H4 B7x,B7S1,B7h.5,VTCN1 + + Unidentified Inhibition
B7-H6 NCR3LG1,NR3L1 - + NKp30 Activation
B7-H7 HHLA2,B7y + + CD28H Activation/Inhibition
Product list
  • Inhibition
  • Activation
  • Activation/Inhibition
Molecule Cat. No. Host Product Description Structure
Molecule Cat. No. Host Product Description Structure
Molecule Cat. No. Host Product Description Structure
Data assay

High purity verified by MALS


The purity of Human B7-H3, His Tag (Cat. No. B73-H52E2) is more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

High batch to batch consistency

Designed for different applications of drug development

Application 1: Development and screening of antibody drugs

Immobilized Human ICOS, Fc Tag (Cat. No. ICS-H5258) at 1 μg/mL (100 μL/well) can bind Human B7-H2, His Tag (Cat. No. B72-H5221) with a linear range of 5-78 ng/mL (QC tested).  
 

Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.8260 μg/mL (Routinely tested).

Application 2: Affinity detection of antibody drugs

Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200)(Routinely tested).

Application 3: Cell-based assay

Flow Cytometry assay shows that Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 0.3 μg/mL (Routinely tested).
 
 

FACS analysis shows that the binding of Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-Human CTLA-4 antibody. The concentration of B7-1 used is 0.3 μg/mL. The IC50 is 3.025 μg/mL (Routinely tested).

Human B7-H3 (4Ig), His Tag (Cat. No. B7B-H52E7) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 7.95 μg/mL (Routinely tested).

Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).

Customer reviews
ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message